Drug Trial Radar · NCT05618314
Study of AT-527 in Subjects With Normal and Impaired Renal Function
Last checked: Nov 20, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Oct 17, 2022
Primary completion
Jun 15, 2024
Study completion Jun 15, 2024
Sponsor
- Lead sponsor
- Atea Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study of AT-527 in Subjects with Normal and Impaired Renal Function
Conditions
- Healthy Volunteer
- Renal Impairment
Interventions
AT-527Drug
single dose AT-527
AT-527Drug
Single dose of AT-527 pre- and post-dialysis
AT-527 and ProbenecidDrug
Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK) of AT-527 Maximum plasma concentration (Cmax)Time frame: Day 1
- Pharmacokinetics (PK) of AT-527 Area under the plasma concentration-time curve (AUC)Time frame: Day 1
- Pharmacokinetics (PK) of AT-527 AUCTime frame: Day 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Atea Study Site
Québec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.